Boehringer Ingelheim’s UK & Ireland managing director Uday Bose has been elected chair of the European Medicines Group (EMG).
Established in 2001, the EMG is a voice for UK operations of continental European headquartered research-based pharmaceutical companies and seeks to promote a dialogue between the UK Government, the NHS and wider stakeholders.
“I am delighted to share the news that I have been elected chair,” Bose wrote in a LinkedIn post, adding: “I look forward to working with the EMG to help support the ambition set out in the Life Sciences Vision for the UK to be a world leader in life sciences.”
Bose is a vastly experienced pharmaceutical industry leader who has had over 20 years’ experience spanning general management, health economics, sales and marketing roles with national, regional and global accountability.
With significant speciality care experience including all aspects of commercialisation for early and late stage assets, he has held the current post at BI since 2018, after spending four years at the company’s corporate HQ where he held the position of corporate vice president/head of Global Marketing, Therapeutic Area, Oncology.
Previous to joining BI, Bose has held senior positions with several other pharmaceutical companies for over 20 years.